PulseJournal ClubResearchersJournalsExplore
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
March 27, 2026Discover OncologyOpen Access

The palmitoylation enzyme ZDHHC2 promotes esophageal cancer progression via N-acetylaspartylglutamate

View Full Paper
Ask AI
Bookmark
Share

Authors

SPSimin PengYWYing WāngFZFen Zhou

Discussion

Loading...

Member takes

Overview

Genome-wide analysis shows ZDHHC2 influences esophageal cancer risk, suggesting new treatment pathways.

Key Points

  • The study investigates the role of ZDHHC2 and its metabolite NAAG in esophageal cancer progression.
  • Utilized data from genome-wide association studies (GWAS)
  • Applied a two-sample Mendelian randomization analysis
  • Explored the mediating role of N-acetylaspartylglutamate (NAAG)
  • Elevated ZDHHC2 expression correlates significantly with increased esophageal cancer risk (OR = 1.178, P = 0.031)
  • NAAG accounts for 6.1% of the total effect in the ZDHHC2-cancer relationship (P = 0.038)

Cite This Study

Peng et al. (2026) studied this question.

synapsesocial.com/papers/69c61ff615a0a509bde185b1https://doi.org/10.1007/s12672-026-04907-3
View Full Paper
Ask AI
Bookmark
Share